Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.

Background Bone-modifying agents are effective for treatment of breast cancer patients with bone metastases. Since their action is mediated through suppression of the osteoclast function, their efficacy can be determined by monitoring bone turnover markers. However, the clinical significance of these markers is yet to be compared.